Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)

BOSTON and STOCKHOLM, April 16, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announ... Biopharmaceuticals, Oncology, FDA Aprea Therapeutics, p53, myelodysplastic syndromes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news